{"transactions":[{"id":2934354,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":144461,"kind":"person","name":"Schwabe Stefan K.F.","position":1,"cik":"0001557657","reported_name":"Schwabe Stefan K.F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CMO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-12-22T22:49:47.000Z","date":"2020-12-21","kind":"exercise","acquired":false,"shares":46347,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests in four equal annual installments beginning on March 1, 2017."}],"balance_after":0,"derivative":{"exercise_price":12.98,"expiration_date":"2026-03-01","underlying":"Common Stock","underlying_shares":46347},"source":{"system":"sec-edgar","filing":"0001104659-20-138671","document":"tm2039215-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465920138671/tm2039215-1_4seq1.xml","form_type":"4"}},{"id":2934353,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":144461,"kind":"person","name":"Schwabe Stefan K.F.","position":1,"cik":"0001557657","reported_name":"Schwabe Stefan K.F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CMO"}}],"security":"Common Stock","published_at":"2020-12-22T22:49:47.000Z","date":"2020-12-21","kind":"sale","acquired":false,"shares":46347,"price":22.1042,"value":1024463.3574,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.0000 to $22.2500, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. (\"Supernus\"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":2772,"source":{"system":"sec-edgar","filing":"0001104659-20-138671","document":"tm2039215-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465920138671/tm2039215-1_4seq1.xml","form_type":"4"}},{"id":2934352,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":144461,"kind":"person","name":"Schwabe Stefan K.F.","position":1,"cik":"0001557657","reported_name":"Schwabe Stefan K.F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CMO"}}],"security":"Common Stock","published_at":"2020-12-22T22:49:47.000Z","date":"2020-12-21","kind":"exercise","acquired":true,"shares":46347,"price":12.98,"value":601584.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2020."}],"balance_after":49119,"source":{"system":"sec-edgar","filing":"0001104659-20-138671","document":"tm2039215-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465920138671/tm2039215-1_4seq1.xml","form_type":"4"}},{"id":2944119,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":144461,"kind":"person","name":"Schwabe Stefan K.F.","position":1,"cik":"0001557657","reported_name":"Schwabe Stefan K.F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CMO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-12-16T01:20:51.000Z","date":"2020-12-14","kind":"exercise","acquired":false,"shares":3653,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests in four equal annual installments beginning on March 1, 2017."}],"balance_after":46347,"derivative":{"exercise_price":12.98,"expiration_date":"2026-03-01","underlying":"Common Stock","underlying_shares":3653},"source":{"system":"sec-edgar","filing":"0001104659-20-135882","document":"tm2038590-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465920135882/tm2038590-1_4seq1.xml","form_type":"4"}},{"id":2944118,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":144461,"kind":"person","name":"Schwabe Stefan K.F.","position":1,"cik":"0001557657","reported_name":"Schwabe Stefan K.F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CMO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-12-16T01:20:51.000Z","date":"2020-12-14","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests in four equal annual installments beginning on March 3, 2016."}],"balance_after":0,"derivative":{"exercise_price":9.13,"expiration_date":"2025-03-03","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-20-135882","document":"tm2038590-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465920135882/tm2038590-1_4seq1.xml","form_type":"4"}},{"id":2944117,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":144461,"kind":"person","name":"Schwabe Stefan K.F.","position":1,"cik":"0001557657","reported_name":"Schwabe Stefan K.F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CMO"}}],"security":"Common Stock","published_at":"2020-12-16T01:20:51.000Z","date":"2020-12-14","kind":"sale","acquired":false,"shares":3653,"price":22.0007,"value":80368.5571,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.0000 to $22.0100, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. (\"Supernus\"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":2772,"source":{"system":"sec-edgar","filing":"0001104659-20-135882","document":"tm2038590-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465920135882/tm2038590-1_4seq1.xml","form_type":"4"}},{"id":2944116,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":144461,"kind":"person","name":"Schwabe Stefan K.F.","position":1,"cik":"0001557657","reported_name":"Schwabe Stefan K.F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CMO"}}],"security":"Common Stock","published_at":"2020-12-16T01:20:51.000Z","date":"2020-12-14","kind":"sale","acquired":false,"shares":50000,"price":21.8579,"value":1092895.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.5500 to $22.0300, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. (\"Supernus\"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":6425,"source":{"system":"sec-edgar","filing":"0001104659-20-135882","document":"tm2038590-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465920135882/tm2038590-1_4seq1.xml","form_type":"4"}},{"id":2944115,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":144461,"kind":"person","name":"Schwabe Stefan K.F.","position":1,"cik":"0001557657","reported_name":"Schwabe Stefan K.F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CMO"}}],"security":"Common Stock","published_at":"2020-12-16T01:20:51.000Z","date":"2020-12-14","kind":"exercise","acquired":true,"shares":3653,"price":12.98,"value":47415.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2020."}],"balance_after":56425,"source":{"system":"sec-edgar","filing":"0001104659-20-135882","document":"tm2038590-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465920135882/tm2038590-1_4seq1.xml","form_type":"4"}},{"id":2944114,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":144461,"kind":"person","name":"Schwabe Stefan K.F.","position":1,"cik":"0001557657","reported_name":"Schwabe Stefan K.F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CMO"}}],"security":"Common Stock","published_at":"2020-12-16T01:20:51.000Z","date":"2020-12-14","kind":"exercise","acquired":true,"shares":50000,"price":9.13,"value":456500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2020."}],"balance_after":52772,"source":{"system":"sec-edgar","filing":"0001104659-20-135882","document":"tm2038590-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465920135882/tm2038590-1_4seq1.xml","form_type":"4"}},{"id":3248646,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":144461,"kind":"person","name":"Schwabe Stefan K.F.","position":1,"cik":"0001557657","reported_name":"Schwabe Stefan K.F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CMO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-02-25T22:24:35.000Z","date":"2020-02-21","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in four equal annual installments beginning on February 21, 2021."}],"balance_after":50000,"derivative":{"exercise_price":23.99,"expiration_date":"2030-02-21","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-20-024850","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465920024850/a4.xml","form_type":"4"}},{"id":3631414,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":144461,"kind":"person","name":"Schwabe Stefan K.F.","position":1,"cik":"0001557657","reported_name":"Schwabe Stefan K.F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President R&D"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-27T00:28:01.000Z","date":"2019-02-22","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in four equal annual installments beginning on February 22, 2020."}],"balance_after":40000,"derivative":{"exercise_price":36.75,"expiration_date":"2029-02-22","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-19-010801","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465919010801/a4.xml","form_type":"4"}},{"id":3888106,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":144461,"kind":"person","name":"Schwabe Stefan K.F.","position":1,"cik":"0001557657","reported_name":"Schwabe Stefan K.F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP R&D, CMO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-06-19T21:51:37.000Z","date":"2018-06-18","kind":"exercise","acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a Rule 10b5-1 trading plan adopted May 17, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option became exercisable in four equal installments beginning on January 21, 2015, which was the first anniversary of the date on which the option was granted."}],"balance_after":0,"derivative":{"exercise_price":9.24,"expiration_date":"2024-01-21","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-18-041086","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465918041086/a4.xml","form_type":"4"}},{"id":3888105,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":144461,"kind":"person","name":"Schwabe Stefan K.F.","position":1,"cik":"0001557657","reported_name":"Schwabe Stefan K.F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP R&D, CMO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-06-19T21:51:37.000Z","date":"2018-06-18","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a Rule 10b5-1 trading plan adopted May 17, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted."}],"balance_after":0,"derivative":{"exercise_price":7.9,"expiration_date":"2023-02-05","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-18-041086","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465918041086/a4.xml","form_type":"4"}},{"id":3888104,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":144461,"kind":"person","name":"Schwabe Stefan K.F.","position":1,"cik":"0001557657","reported_name":"Schwabe Stefan K.F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP R&D, CMO"}}],"security":"Common Stock","published_at":"2018-06-19T21:51:37.000Z","date":"2018-06-18","kind":"sale","acquired":false,"shares":60000,"price":54.3892,"value":3263352.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a Rule 10b5-1 trading plan adopted May 17, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.000 to $54.900, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. (\"Supernus\"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":1967,"source":{"system":"sec-edgar","filing":"0001104659-18-041086","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465918041086/a4.xml","form_type":"4"}},{"id":3888103,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":144461,"kind":"person","name":"Schwabe Stefan K.F.","position":1,"cik":"0001557657","reported_name":"Schwabe Stefan K.F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP R&D, CMO"}}],"security":"Common Stock","published_at":"2018-06-19T21:51:37.000Z","date":"2018-06-18","kind":"exercise","acquired":true,"shares":40000,"price":9.24,"value":369600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a Rule 10b5-1 trading plan adopted May 17, 2018."}],"balance_after":61967,"source":{"system":"sec-edgar","filing":"0001104659-18-041086","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465918041086/a4.xml","form_type":"4"}},{"id":3888102,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":144461,"kind":"person","name":"Schwabe Stefan K.F.","position":1,"cik":"0001557657","reported_name":"Schwabe Stefan K.F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP R&D, CMO"}}],"security":"Common Stock","published_at":"2018-06-19T21:51:37.000Z","date":"2018-06-18","kind":"exercise","acquired":true,"shares":20000,"price":7.9,"value":158000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a Rule 10b5-1 trading plan adopted May 17, 2018."}],"balance_after":21967,"source":{"system":"sec-edgar","filing":"0001104659-18-041086","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465918041086/a4.xml","form_type":"4"}},{"id":4051358,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":144461,"kind":"person","name":"Schwabe Stefan K.F.","position":1,"cik":"0001557657","reported_name":"Schwabe Stefan K.F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President R&D"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-02-16T21:57:41.000Z","date":"2018-02-14","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in four equal annual installments beginning on February 14, 2019."}],"balance_after":30000,"derivative":{"exercise_price":39.4,"expiration_date":"2028-02-14","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-18-010410","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465918010410/a4.xml","form_type":"4"}},{"id":4212605,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":144461,"kind":"person","name":"Schwabe Stefan K.F.","position":1,"cik":"0001557657","reported_name":"Schwabe Stefan K.F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President R&D"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-09-11T23:22:57.000Z","date":"2017-09-07","kind":"exercise","acquired":false,"shares":95000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option became exercisable in four equal installments beginning on August 9, 2013, which was the first anniversary of the date on which the option was granted."}],"balance_after":0,"derivative":{"exercise_price":12.92,"expiration_date":"2022-08-09","underlying":"Common Stock","underlying_shares":95000},"source":{"system":"sec-edgar","filing":"0001104659-17-056610","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465917056610/a4.xml","form_type":"4"}},{"id":4212604,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":144461,"kind":"person","name":"Schwabe Stefan K.F.","position":1,"cik":"0001557657","reported_name":"Schwabe Stefan K.F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President R&D"}}],"security":"Common Stock","published_at":"2017-09-11T23:22:57.000Z","date":"2017-09-07","kind":"sale","acquired":false,"shares":95000,"price":46.585,"value":4425575.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.000 to $47.800, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. (\"Supernus\"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":1855,"source":{"system":"sec-edgar","filing":"0001104659-17-056610","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465917056610/a4.xml","form_type":"4"}},{"id":4212603,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":144461,"kind":"person","name":"Schwabe Stefan K.F.","position":1,"cik":"0001557657","reported_name":"Schwabe Stefan K.F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President R&D"}}],"security":"Common Stock","published_at":"2017-09-11T23:22:57.000Z","date":"2017-09-07","kind":"exercise","acquired":true,"shares":95000,"price":12.92,"value":1227400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an aggregate of 324 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan subsequent to the date of the Reporting Person's most recent filing on Form 4."}],"balance_after":96855,"source":{"system":"sec-edgar","filing":"0001104659-17-056610","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465917056610/a4.xml","form_type":"4"}},{"id":4420859,"issuer":{"id":4333,"kind":"organization","name":"SUPERNUS PHARMACEUTICALS, INC."},"owners":[{"id":144461,"kind":"person","name":"Schwabe Stefan K.F.","position":1,"cik":"0001557657","reported_name":"Schwabe Stefan K.F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President R&D"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-02-28T02:59:25.000Z","date":"2017-02-24","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in four equal installments beginning on February 24, 2018."}],"balance_after":50000,"derivative":{"exercise_price":25.3,"expiration_date":"2027-02-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-17-012179","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465917012179/a4.xml","form_type":"4"}}]}